Position in ELVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$43,985,837
New position
Shares Held
866,716
first reported quarter
Ownership
1.18%
of shares outstanding
% of Portfolio
5.41%
of 13F equity value
Holder Rank
#24
of 210 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Tri Locum Partners LP holds $480,651,345 across 12 Biotechnology names. ELVN ranks #5 (9.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
201,791 | $100,235,643 | |
| 2 | ASND |
Ascendis Pharma A/S
|
258,740 | $69,011,132 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
219,308 | $53,680,019 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
221,720 | $53,427,868 | |
| 5 | ELVN |
Enliven Therapeutics, Inc.
This page
|
866,716 | $43,985,837 | |
| 6 | ARGX |
Argenx SE
|
41,596 | $38,591,520 | |
| 7 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
68,273 | $36,659,187 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
151,822 | $28,433,224 |
All Filings in ELVN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $43,985,837 | 866,716 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||